NYVAC C

Drug Profile

NYVAC C

Alternative Names: NYVAC poxvirus vector + clade C gag-pol-nef + env immunogen; NYVAC-HIV-C

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator EuroVacc Foundation; GENEART; sanofi pasteur; University of Regensburg
  • Developer EuroVacc Foundation
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 21 Sep 2015 No recent reports on development identified - Phase-I/II for HIV-1 infections (Prevention) in Switzerland, United Kingdom, France (IM)
  • 13 Apr 2010 The vaccine is still in active development
  • 23 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top